Proactive Investors - Run By Investors For Investors

Celsion liver cancer data underscores co's potential of its technology

ThermoDox is a heat-activated method of carrying chemotherapy to a target area.
Celsion liver cancer data underscores co's potential of its technology
The technology is being used to treat liver cancer.

Celsion Corp (NASDAQ:CLSN) shares jumped 17% in pre-market trade after it unveiled another round of survival data that underscored the potential of its technology in patients with primary liver cancer.

ThermoDox is a heat-activated method of carrying chemotherapy to a target area.

It was used in combination with radio frequency ablation, where heat generated from radio waves is used to a kill a tumour.

However with some tumours the outer edges, or margins, survive the process. ThermoDox uses heat sensitive liposomes that contain doxorubicin to kill off the remnant cancer.

The latest update from the clinical trial revealed that 41% of the patient group saw a significant improvement in survival when using the combination therapy compared with those people simply receiving radio frequency ablation (RFA) alone.

The data were even more compelling in the Chinese patient population.

“Data from the HEAT Study have consistently been a foundation and provides additional evidence for our thesis that ThermoDox, when combined with RFA standardised to a minimum of 45 minutes for intermediate size lesions has the potential to significantly improve survival in primary liver cancer, where the current overall survival rate is far too short,” said Nicholas Borys, Celsion's chief medical officer.

“These findings, if borne out in our ongoing OPTIMA trial, will position ThermoDox as a potentially curative treatment in primary liver cancer.”

View full CLSN profile View Profile

Celsion Timeline

Related Articles

Oncoprex
October 17 2018
The biotech was founded by an investment group led by scientists and driven by a no-nonsense CEO whose stake is more than just business as usual
Vial of pills
June 25 2018
Cosmos is a modern company, but the trade routes it relies on are ancient
scientist in lab
December 20 2018
Data from Midatech's MTD201 drug has validated the company's Q-Sphera sustained release technology, and other, bigger players are starting to sit up and take note
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use